Group | Baseline | Week 1 | Week 2 | Week 4 | Week 6 | Week 8 |
|---|
Placebo
| 48.6 ± 5.2 | 49.0 ± 5.8 | 46.6 ± 5.9 | 43.5 ± 5.8 | 38.8 ± 5.9 * | 35.3 ± 6.3 ** |
A
| 51.5 ± 6.4 | 43.5 ± 6.9 | 41.4 ± 6.7 ** | 35.0 ± 6.2 *** | 36.2 ± 6.2 *** | 31.8 ± 6.1 *** |
B
| 46.4 ± 5.6 | 42.0 ± 5.9 * | 38.6 ± 6.0 *** | 32.6 ± 5.2 *** | 31.5 ± 5.3 *** | 28.5 ± 3.9 *** |
C
| 44.8 ± 5.5 | 42.3 ± 5.2 | 39.0 ± 5.1 ** | 32.0 ± 4.4 *** | 28.7 ± 4.5 *** | 25.6 ± 4.4 *** |
- Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, ** p < 0.001. Note the p values for groups A and C approached significance at week one (p = 0.051 and 0.053).
